早期三阴性乳腺癌的旅程:开始,结束,以及中间的一切
Hyo Sook Han1, Praveen Vikas2, Ricardo L B Costa1
1Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
概括
三重阴性乳腺癌 (TNBC) 治疗正在与免疫疗法一起发展. 本综述涵盖了早期TNBC建议和管理免疫治疗副作用,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有高死亡率的侵袭性亚型.
- 早期的TNBC管理传统上涉及化疗和手术.
- 免疫疗法是TNBC的新治疗选择.
研究的目的:
- 对早期TNBC的当前治疗指南进行审查.
- 讨论在TNBC中与免疫治疗相关的不良事件的管理.
- 为了平衡免疫疗法的疗效与毒性管理.
主要方法:
- 对当前治疗建议的文献综述.
- 分析与免疫疗法相关的不良事件.
- 综合临床试验数据和专家意见.
主要成果:
- 既定的化疗和手术方案仍然至关重要.
- 免疫疗法显示出有希望的结果,但需要仔细监测毒性.
- 平衡治疗疗效和管理与免疫相关的不良事件是关键.
结论:
- 目前的TNBC治疗结合了既定疗法和新兴的免疫疗法选择.
- 免疫疗法毒性的有效管理对于患者的安全和治疗成功至关重要.
- 需要进一步的研究,以优化免疫疗法在早期TNBC的使用.
更多相关视频
相关概念视频
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer-Critical Genes I: Proto-oncogenes
9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402


